-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Cancer patients are at higher risk of severe COVID-19 (COVID-19)
Cancer patients are at higher risk of severe COVID-19
Patients and methods: In this interventional prospective multi-cohort study, patients with solid tumors receiving chemotherapy, immunotherapy, targeted or hormone therapy were given start-up and booster doses of BNT162b2 covid19 vaccine every 21 days, and received ritux Patients with hematological malignancies after ximab or allogeneic hematopoietic stem cell transplantation
Results: Local and systemic adverse events (AEs) were mostly mild to moderate (only 1%-3% of patients experienced severe AEs)
Figure 1 Local and systemic adverse events (AEs) were reported within 7 days after the initiation and enhancement of BNT162b2 vaccination; (A) local and (C) systemic adverse reactions pooled from all study cohorts, and based on the total study population It is expressed as a percentage (200 people were vaccinated and 197 people were boosted)
Figure 2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-RBD antibody response after administration of BNT162b2 vaccine; virus neutralization test, neutralization titer is 50% (NT50), defined as SARS-CoV -2 (2019nCoV-Italia-INMI1 strain, number 008V-03893, 5th generation) the dilution (reciprocal titer) of the 50% neutralized sample in the infection well
Figure 3 Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) produces neutralizing antibody response after vaccination with BNT162b2 vaccine; virus neutralization test, the neutralization titer is 50% neutralization titer (NT50), definition It is the sample dilution (reciprocal titer) of 50% neutralization in the SARS-CoV-2 (2019nCoV-Italia-INMI1 strain, number 008V-03893, 5th generation) infection well
Conclusion: BNT162b2 vaccine is well tolerated in actively treated tumor patients
The BNT162b2 vaccine is well tolerated in actively treated cancer patients
Peeters M, Verbruggen L, Teuwen L,et al, Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment .
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
in this message